NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has closed its public offering, raising $27.5 million in gross proceeds.

The firm offered 5.5 million shares at $5 per share. Aegis Capital was the sole book-running manager for the offering. Rosetta granted the underwriter a 45-day option to purchase up to 825,000 additional shares to cover any overallotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.